MilliporeSigma
  • Home
  • Search Results
  • In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.

Antimicrobial agents and chemotherapy (2014-05-29)
J P Bilello, L B Lallos, J F McCarville, M La Colla, I Serra, C Chapron, J M Gillum, C Pierra, D N Standring, M Seifer
ABSTRACT

The hepatitis C virus (HCV) nonstructural 5A (NS5A) protein is a clinically validated target for drugs designed to treat chronic HCV infection. This study evaluated the in vitro activity, selectivity, and resistance profile of a novel anti-HCV compound, samatasvir (IDX719), alone and in combination with other antiviral agents. Samatasvir was effective and selective against infectious HCV and replicons, with 50% effective concentrations (EC50s) falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons and with a 10-fold EC50 shift in the presence of 40% human serum in the genotype 1b replicon. The EC90/EC50 ratio was low (2.6). A 50% cytotoxic concentration (CC50) of >100 μM provided a selectivity index of >5 × 10(7). Resistance selection experiments (with genotype 1a replicons) and testing against replicons bearing site-directed mutations (with genotype 1a and 1b replicons) identified NS5A amino acids 28, 30, 31, 32, and 93 as potential resistance loci, suggesting that samatasvir affects NS5A function. Samatasvir demonstrated an overall additive effect when combined with interferon alfa (IFN-α), ribavirin, representative HCV protease, and nonnucleoside polymerase inhibitors or the nucleotide prodrug IDX184. Samatasvir retained full activity in the presence of HIV and hepatitis B virus (HBV) antivirals and was not cross-resistant with HCV protease, nucleotide, and nonnucleoside polymerase inhibitor classes. Thus, samatasvir is a selective low-picomolar inhibitor of HCV replication in vitro and is a promising candidate for future combination therapies with other direct-acting antiviral drugs in HCV-infected patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ribavirin, antiviral
Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard
Ribavirin, European Pharmacopoeia (EP) Reference Standard
Supelco
Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Efavirenz, ≥98% (HPLC)
Zidovudine, European Pharmacopoeia (EP) Reference Standard
USP
Zidovudine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
3′-Azido-3′-deoxythymidine, ≥98% (HPLC)
Sigma-Aldrich
Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)
Sigma-Aldrich
DL-Glyceraldehyde 3-phosphate solution, 45-55 mg/mL in H2O
Sigma-Aldrich
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)
Sigma-Aldrich
Lamivudine, ≥98% (HPLC), powder
Sigma-Aldrich
Ritonavir, ≥98% (HPLC)
Ritonavir, European Pharmacopoeia (EP) Reference Standard
Supelco
Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Lamivudine, United States Pharmacopeia (USP) Reference Standard
USP
Doxorubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Lamivudine, European Pharmacopoeia (EP) Reference Standard
Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Telbivudine, ≥98% (HPLC)